Description

Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D)[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-sugar/lipid metabolism–C169H256N42O57—-[1]Henderson SJ,et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.Diabetes Obes Metab. 2016 Dec;18(12):1176-1190.|[2]Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020 May;2(5):413-431. —-3788.14–96.37–CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCCC[C@H](NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC(CNC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@@H](N)CC2=CNC=N2)=O)=O)=O)=O)[C@@H](C)O)=O)=O)[C@@H](C)O)=O)=O)=O)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC/N=C(N)N)C(N[C@@H](C)C(N[C@@H](CCC/N=C(N)N)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CC5=CNC6=C5C=CC=C6)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(NCC(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(O)=O)=O.CC(O)=O–Metabolic Disease–DMSO : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)–GCGR—-GPCR/G Protein–Peptides